New Statistical Method Improves Identification of Microbiome Changes Associated with Heart Disease
Researchers introduced BootDA, a new computational method that more accurately identifies which bacteria differ in abundance between healthy and diseased microbiomes by accounting for four major sources of measurement bias. The method outperformed existing approaches in simulations and identified two bacterial genera—Klebsiella and Gemmiger—as refined markers of coronary artery disease. This advance could improve how scientists use microbiome data to understand disease mechanisms and develop diagnostics.
A new statistical method called BootDA addresses longstanding challenges in microbiome analysis by explicitly modeling four sources of bias: loss of total microbial load, measurement inefficiencies across different bacterial taxa, the prevalence of zero counts in sparse data, and contamination. Unlike existing methods, BootDA avoids data transformations and parametric assumptions that can distort results. In computational simulations mimicking real 16S amplicon sequencing data, BootDA achieved higher sensitivity than competing methods (ANCOM-BC2, LinDA, MaAsLin 3, and Wilcoxon tests) while maintaining appropriate false discovery rate control. When applied to a coronary artery disease patient cohort, the method refined the disease signature to two co-enriched bacterial genera and filtered out likely contaminants. The researchers have made BootDA available as an open-source R package and suggest it could be adapted for other sparse, high-dimensional biological datasets.
Limitations & open questions
The study does not discuss potential limitations of the 16S amplicon sequencing approach itself (such as inability to distinguish closely related species or bias toward certain bacterial groups), nor does it provide details on the size or demographic characteristics of the coronary artery disease cohort used for validation. The clinical significance of the identified Klebsiella and Gemmiger enrichment—whether these findings are mechanistically causal or merely correlative—remains unclear from the abstract.
What different sources said
- bioRxivCenter
Bias-mitigated microbiome inference refines coronary artery disease signature
Related
Study reveals IDH1 enzyme's role in cardiac metabolic adaptation during cancer-related stress
Researchers discovered that isocitrate dehydrogenase 1 (IDH1) helps the heart adapt to metabolic stress caused by cancer-related mutations through a previously unknown reductive metabolic pathway. The study used stable isotope tracing and genetic knockout models in rat and mouse heart tissue to show that when mitochondrial metabolism is impaired, IDH1 redirects carbon flux toward glutamine-derived citrate formation. This finding expands understanding of how cardiac metabolism responds to oncometabolic stress and may have implications for managing cardiovascular complications in cancer patients.
AI Framework Reveals How β-Arrestin 1 Protein Changes Shape During Activation
Researchers used a transformer-based artificial intelligence model to analyze how the β-arrestin 1 protein's tail region reorganizes when activated by cell surface receptors. The study examined molecular dynamics simulations comparing the protein in resting and active states, uncovering previously unknown conformational changes. This work could improve understanding of how cells regulate signaling pathways involved in numerous physiological and disease processes.
Study Links Pancreatic Cancer Tissue Stiffness to Tumor Progression and Patient Survival
Researchers combined imaging scans and laboratory tissue analysis to show that pancreatic cancer tumors with greater stiffness—driven by dense collagen buildup—correlate with worse patient survival outcomes. The study of nine patients found that magnetic resonance elastography, a non-invasive imaging technique, can detect mechanical properties that reflect underlying tumor biology. These findings suggest that measuring tissue stiffness through imaging could help doctors better characterize pancreatic cancer and guide treatment decisions.